Navigation Links
Lung Adenocarcinoma-Pipeline Insights, 2014
Date:9/3/2014

NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Lung Adenocarcinoma-Pipeline Insights, 2014

http://www.reportlinker.com/p02278633/-Lung-Adenocarcinoma-Pipeline-Insights-2014.html

SUMMARY
DelveInsight's," Lung Adenocarcinoma-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Lung Adenocarcinoma. This report provides information on the therapeutic development based on the Lung Adenocarcinoma dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Lung Adenocarcinoma
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Lung Adenocarcinoma pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Lung Adenocarcinoma and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Lung Adenocarcinoma
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents

- Lung Adenocarcinoma Overview
- Lung Adenocarcinoma Pipeline Therapeutics
- Lung Adenocarcinoma Therapeutics under Development by Companies
- Lung Adenocarcinoma Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Lung Adenocarcinoma Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Lung Adenocarcinoma Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Lung Adenocarcinoma Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Lung Adenocarcinoma – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Lung Adenocarcinoma – Discontinued Products
- Lung Adenocarcinoma – Dormant Products
- Companies Involved in Therapeutics Development for Lung Adenocarcinoma
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Lung Adenocarcinoma, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Lung Adenocarcinoma Assessment by Monotherapy Products
- Lung Adenocarcinoma Assessment by Combination Products
- Lung Adenocarcinoma Assessment by Route of Administration
- Lung Adenocarcinoma Assessment by Stage and Route of Administration
- Lung Adenocarcinoma Assessment by Molecule Type
- Lung Adenocarcinoma Assessment by Stage and Molecule Type
- Lung Adenocarcinoma Therapeutics – Discontinued Products
- Lung Adenocarcinoma Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Lung Adenocarcinoma, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Lung Adenocarcinoma Assessment by Monotherapy Products
- Lung Adenocarcinoma Assessment by Combination Products
- Lung Adenocarcinoma Assessment by Route of Administration
- Lung Adenocarcinoma Assessment by Stage and Route of Administration
- Lung Adenocarcinoma Assessment by Molecule Type
- Lung Adenocarcinoma Assessment by Stage and Molecule Type

To order this report: Lung Adenocarcinoma-Pipeline Insights, 2014
http://www.reportlinker.com/p02278633/-Lung-Adenocarcinoma-Pipeline-Insights-2014.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 /PRNewswire/ - Demers Ambulances announces its first delivery in the ... Okaloosa County Emergency Medical Services (EMS) consisting of ... LT2 van. Quality Emergency Vehicles in Lecanto, FL ... sale.  This is the latest in Demers, ongoing expansion of ... at Demers. --> Benoit LaFortune , Executive Vice ...
(Date:2/12/2016)...   HeartWare International, Inc . (NASDAQ: HTWR ... discuss its financial results for the three and 12 ... 2016 at 8:00 a.m. ET.  The company plans to ... and webcast.  On the conference call and webcast, management ... fourth quarter and business outlook.   --> ...
(Date:2/12/2016)... Kalifornien, 12. Februar 2016  Sequent Medical, Inc. ... von Patienten für eine Studie zur Sicherheit und ... speziell für die Behandlung von rupturierten intrakraniellen Aneurysmen ... Leiter der Neuroradiologie an der Universitätsklinik Bicètre in ... der CLARYS-Studie hat den ersten Patienten aufgenommen. ...
Breaking Medicine Technology:
(Date:2/12/2016)... Boca Raton, FL (PRWEB) , ... February 12, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – hosted over 250 members of South Florida’s philanthropic community at ...
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of coconut ... Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities the ... the big event. The invitation-only gifting suite, held this year at the W Hollywood ...
(Date:2/12/2016)... NV (PRWEB) , ... February 12, 2016 , ... Fisher ... Las Vegas Mayor John J. Lee, Nevada Military Support Alliance president Scott Bensing, and ... House at the VA Southern Nevada Healthcare System. This will be the first ...
(Date:2/12/2016)... ... 12, 2016 , ... Young Asset Protection, a full service ... the latest charity campaign in their community enrichment program. Art Expression utilizes after-school ... cause are currently being accepted at: http://artexpressioninc.org/ . , Art Expression is ...
(Date:2/12/2016)... New York, NY (PRWEB) , ... February 12, ... ... latest edition of “Revolutionizing Cancer Care.” , The print component of ... in Chicago, Dallas, Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation ...
Breaking Medicine News(10 mins):